NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Stocks to Buy: We have a Buy rating on Max Healthcare Institute Ltd. with our SoTP-based target price of Rs 1,380.
We expect a compound annual growth rate of 18.4%/16.2%/20.5% in revenue/Ebitda/PAT over FY25-27. We value Max on the SoTP basis (35 times enterprise value/Ebitda for hospital business, 26 times EV/Ebitda for Maxlab business, six times EV/sales for Max@home) to arrive at our target price of Rs 1,380.
We remain positive on Max on the back of a robust industry outlook in its focus markets (Delhi, UP, Maharashtra, Punjab, Uttarakhand, Haryana). Along with efficient execution, Max is tripling its bed capacity over the next five years, thus providing strong headroom for growth.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
. Read more on Research Reports by NDTV Profit.Stocks to Buy: The brokerage believes that Max’s expansion via a combination of brownfield, greenfield
and inorganic will drive strong revenue growth. Read MoreResearch Reports
NDTV Profit
